Physiologically‐Based Pharmacokinetic Modelling to Investigate Baricitinib and Tofacitinib Dosing Recommendations for COVID‐19 in Geriatrics

Janus kinase (JAK) inhibitors baricitinib and tofacitinib are recommended by the US National Institutes of Health as immunomodulatory drugs for coronavirus disease 2019 (COVID‐19) treatment. In addition, baricitinib has recently received Emergency Use Authorization from the US Food and Drug Administ...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Ziteng, Chan, Eric Chun Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9087009/
https://www.ncbi.nlm.nih.gov/pubmed/35380176
http://dx.doi.org/10.1002/cpt.2600

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9087009/
https://www.ncbi.nlm.nih.gov/pubmed/35380176
http://dx.doi.org/10.1002/cpt.2600

Ejemplares similares